These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 28860442

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Three cases of lenalidomide-resistant IgA myeloma for which a response was regained after the addition of clarithromycin].
    Kuroda H, Jomen W, Yoshida M, Usami M, Yamada M, Abe T, Sakurai T, Fujii S, Maeda M, Matsuno T, Sato M, Kanari Y, Kato J.
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1179-82. PubMed ID: 25248908
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma.
    Ghosh N, Tucker N, Zahurak M, Wozney J, Borrello I, Huff CA.
    Am J Hematol; 2014 Aug; 89(8):E116-20. PubMed ID: 24723438
    [Abstract] [Full Text] [Related]

  • 6. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
    Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R.
    Am J Hematol; 2010 Sep; 85(9):664-9. PubMed ID: 20645430
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia.
    Coleman M, Leonard J, Lyons L, Pekle K, Nahum K, Pearse R, Niesvizky R, Michaeli J.
    Leuk Lymphoma; 2002 Sep; 43(9):1777-82. PubMed ID: 12685831
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Successful treatment of relapsed and refractory multiple myeloma by using clarithromycin-lenalidomide, low-dose dexamethasone(BiRd), and melphalan-prednisolone(MP)].
    Tsunemine H, Yoshioka S, Sakane E, Akasaka H, Ito K, Kodaka T, Takahashi T.
    Gan To Kagaku Ryoho; 2015 May; 42(5):605-7. PubMed ID: 25981655
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
    Tufail M, Siegel DS, McBride L, Bilotti E, Bello E, Anand P, Olivo K, Bendarz U, McNeill A, Vesole DH.
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):186-90. PubMed ID: 22381702
    [Abstract] [Full Text] [Related]

  • 13. The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma.
    Kobayashi T, Miura M, Abumiya M, Niioka T, Kanno S, Takahashi N.
    Ann Hematol; 2018 Jun; 97(6):1097-1099. PubMed ID: 29427183
    [No Abstract] [Full Text] [Related]

  • 14. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE.
    Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
    [Abstract] [Full Text] [Related]

  • 15. "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
    Katodritou E, Vadikolia C, Lalagianni C, Kotsopoulou M, Papageorgiou G, Kyrtsonis MC, Matsouka P, Giannakoulas N, Kyriakou D, Karras G, Anagnostopoulos N, Michali E, Briasoulis E, Hatzimichael E, Spanoudakis E, Zikos P, Tsakiridou A, Tsionos K, Anargyrou K, Symeonidis A, Maniatis A, Terpos E.
    Ann Hematol; 2014 Jan; 93(1):129-39. PubMed ID: 23892921
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Lenalidomide and low-dose dexamethasone therapy for Japanese patients with newly diagnosed multiple myeloma: updated results of the MM-025 study].
    Ando K, Chou T, Suzuki K, Shinagawa A, Uchida T, Taniwaki M, Hirata H, Ishizawa K, Matsue K, Okamoto S, Otsuka M, Matsumoto M, Iida S, Matsumura I, Ikeda T, Takezako N, Ogaki Y, Midorikawa S, Houck V, Ervin-Haynes A, Terui Y.
    Rinsho Ketsueki; 2017 Jan; 58(11):2219-2226. PubMed ID: 29212972
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial.
    Puig N, Hernández MT, Rosiñol L, González E, de Arriba F, Oriol A, González-Calle V, Escalante F, de la Rubia J, Gironella M, Ríos R, García-Sánchez R, Arguiñano JM, Alegre A, Martín J, Gutiérrez NC, Calasanz MJ, Martín ML, Couto MDC, Casanova M, Arnao M, Pérez-Persona E, Garzón S, González MS, Martín-Sánchez G, Ocio EM, Coleman M, Encinas C, Vale AM, Teruel AI, Cortés-Rodríguez M, Paiva B, Cedena MT, San-Miguel JF, Lahuerta JJ, Bladé J, Niesvizky R, Mateos MV.
    Blood Cancer J; 2021 May 21; 11(5):101. PubMed ID: 34021118
    [Abstract] [Full Text] [Related]

  • 20. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
    Morris TC, Kettle PJ, Drake M, Jones FC, Hull DR, Boyd K, Morrison A, Clarke P, O'Reilly P, Quinn J.
    Br J Haematol; 2008 Nov 21; 143(3):349-54. PubMed ID: 18759764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.